Genmab AS experienced a significant boost in its stock price following promising trial results for its lymphoma treatment.
Shares of Genmab AS (NASDAQ:GMAB) surged 10.73% yesterday, closing at CA$38.48. This increase was driven by positive results from a Phase 3 trial of its lymphoma drug, epcoritamab, in combination with AbbVie's R-CHOP treatment.
Investor takeaway: The strong trial results may position Genmab as a leader in the lymphoma treatment market, potentially leading to increased revenue and market share.
Advertisement
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$24.01B
P/E
27.5x
52W high
$40.17
52W low
$23.62
1W change
+8.82%
Beta
0.65
Analyst Price Targets
Based on 11 analysts covering GMAB · as of Oct 6, 2026
Wall Street analysts forecast GMAB stock price to rise 6.3% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
C$40.92
+6.3% Upside
Previously C$39.05 on Oct 5, 2026
Current Price
C$38.48
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
40.3%
Annualized
90-Day Vol
35.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$46.00
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$40.84 | C$35.53 – C$46.94 |
| 60 trading days | C$43.34 | C$35.60 – C$52.77 |
| 90 trading days | C$46.00 | C$36.15 – C$58.54 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
10.73% Surge
Genmab's stock price jumped after the announcement of a 51% reduction in the risk of disease progression or death in lymphoma patients.
Bull case
The positive trial results suggest a significant advancement in treatment options for diffuse large B-cell lymphoma. This could lead to increased sales and a stronger market position for Genmab.
Bear case
Despite the good news, the company still faces uncertainties regarding regulatory approvals and market competition, which could affect its future performance.
Advertisement
Positive Trial Results Drive Stock Surge
Genmab's stock jumped after the company and AbbVie announced that their combination treatment for newly diagnosed diffuse large B-cell lymphoma significantly reduced the risk of disease progression or death by 51%. This groundbreaking result from the Phase 3 EPCORE DLBCL-2 study marks a potential shift in the treatment landscape for this aggressive form of cancer.
Market Reaction and Future Outlook
The market reacted positively to Genmab's announcement, showing investor confidence in the company's future prospects. Analysts suggest that if regulatory approvals follow, Genmab could see substantial growth in revenue and market share, enhancing its position in the competitive oncology market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
